Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $318.33 to a high of $329.87. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $322.75 on volume of 361,000 …
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets …
Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q …
Liberty Cap Mngmt Inc reported 0.34% stake. Blair William & Company Il has 0.06% invested in Biogen Inc. (NASDAQ:BIIB) for 208 shares. Dearborn Ptnrs Llc …